FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159808529> ?p ?o ?g. }

• W3159808529 endingPage "3222" @default.
• W3159808529 startingPage "3203" @default.
• W3159808529 abstract "Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody under development to improve motor function in patients with spinal muscular atrophy, a rare neuromuscular disease. This phase 1 double-blind, placebo-controlled study assessed safety, pharmacokinetic parameters, pharmacodynamics (serum latent myostatin), and immunogenicity of single and multiple ascending doses of apitegromab in healthy adult subjects. Subjects were administered single intravenous ascending doses of apitegromab of 1, 3, 10, 20, 30 mg/kg or placebo, and multiple intravenous ascending doses of apitegromab of 10, 20, 30 mg/kg or placebo. Following single ascending doses, the pharmacokinetic parameters of apitegromab appeared to be similar across all dose groups, following a biphasic pattern of decline in the concentration–time curve. The mean apparent terminal t1/2 after single intravenous doses of apitegromab ranged from 24 to 31 days across dose groups. Dose-related increases were observed in Cmax following multiple ascending doses. Single and multiple apitegromab doses resulted in dose-dependent and sustained increases in serum latent myostatin, indicating robust target engagement. Apitegromab was safe and well tolerated, on the basis of the adverse event (AE) profile with no clinically meaningful changes in baseline vital signs, electrocardiograms, or clinical laboratory parameters and no anti-drug antibody formation. These results support continued investigation of apitegromab for the treatment of patients with milder forms (type 2 and 3) of spinal muscular atrophy." @default.
• W3159808529 created "2021-05-10" @default.
• W3159808529 creator A5000780851 @default.
• W3159808529 creator A5017801560 @default.
• W3159808529 creator A5041756626 @default.
• W3159808529 creator A5041785213 @default.
• W3159808529 creator A5050749798 @default.
• W3159808529 creator A5058713541 @default.
• W3159808529 creator A5073384262 @default.
• W3159808529 creator A5074295156 @default.
• W3159808529 creator A5087903486 @default.
• W3159808529 creator A5088915722 @default.
• W3159808529 creator A5089088185 @default.
• W3159808529 creator A5089488814 @default.
• W3159808529 date "2021-05-08" @default.
• W3159808529 modified "2023-10-14" @default.
• W3159808529 title "A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy" @default.
• W3159808529 cites W1702490096 @default.
• W3159808529 cites W1867779249 @default.
• W3159808529 cites W1871235281 @default.
• W3159808529 cites W1971189666 @default.
• W3159808529 cites W1980477780 @default.
• W3159808529 cites W1987132484 @default.
• W3159808529 cites W2023960001 @default.
• W3159808529 cites W2025463260 @default.
• W3159808529 cites W2114796514 @default.
• W3159808529 cites W2165235225 @default.
• W3159808529 cites W2166485013 @default.
• W3159808529 cites W2166877291 @default.
• W3159808529 cites W2507871962 @default.
• W3159808529 cites W2753097429 @default.
• W3159808529 cites W2789599716 @default.
• W3159808529 cites W2790085936 @default.
• W3159808529 cites W2792102363 @default.
• W3159808529 cites W2883614888 @default.
• W3159808529 cites W2912779195 @default.
• W3159808529 cites W2920823484 @default.
• W3159808529 cites W2965978838 @default.
• W3159808529 cites W3005505738 @default.
• W3159808529 cites W3023312253 @default.
• W3159808529 cites W3035669996 @default.
• W3159808529 doi "https://doi.org/10.1007/s12325-021-01757-z" @default.
• W3159808529 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8189951" @default.
• W3159808529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33963971" @default.
• W3159808529 hasPublicationYear "2021" @default.
• W3159808529 type Work @default.
• W3159808529 sameAs 3159808529 @default.
• W3159808529 citedByCount "16" @default.
• W3159808529 countsByYear W31598085292021 @default.
• W3159808529 countsByYear W31598085292022 @default.
• W3159808529 countsByYear W31598085292023 @default.
• W3159808529 crossrefType "journal-article" @default.
• W3159808529 hasAuthorship W3159808529A5000780851 @default.
• W3159808529 hasAuthorship W3159808529A5017801560 @default.
• W3159808529 hasAuthorship W3159808529A5041756626 @default.
• W3159808529 hasAuthorship W3159808529A5041785213 @default.
• W3159808529 hasAuthorship W3159808529A5050749798 @default.
• W3159808529 hasAuthorship W3159808529A5058713541 @default.
• W3159808529 hasAuthorship W3159808529A5073384262 @default.
• W3159808529 hasAuthorship W3159808529A5074295156 @default.
• W3159808529 hasAuthorship W3159808529A5087903486 @default.
• W3159808529 hasAuthorship W3159808529A5088915722 @default.
• W3159808529 hasAuthorship W3159808529A5089088185 @default.
• W3159808529 hasAuthorship W3159808529A5089488814 @default.
• W3159808529 hasBestOaLocation W31598085291 @default.
• W3159808529 hasConcept C111113717 @default.
• W3159808529 hasConcept C112705442 @default.
• W3159808529 hasConcept C126322002 @default.
• W3159808529 hasConcept C142724271 @default.
• W3159808529 hasConcept C197934379 @default.
• W3159808529 hasConcept C204787440 @default.
• W3159808529 hasConcept C22979827 @default.
• W3159808529 hasConcept C27081682 @default.
• W3159808529 hasConcept C2777488582 @default.
• W3159808529 hasConcept C2778558090 @default.
• W3159808529 hasConcept C2779134260 @default.
• W3159808529 hasConcept C2779959927 @default.
• W3159808529 hasConcept C42219234 @default.
• W3159808529 hasConcept C71924100 @default.
• W3159808529 hasConcept C90924648 @default.
• W3159808529 hasConcept C98274493 @default.
• W3159808529 hasConceptScore W3159808529C111113717 @default.
• W3159808529 hasConceptScore W3159808529C112705442 @default.
• W3159808529 hasConceptScore W3159808529C126322002 @default.
• W3159808529 hasConceptScore W3159808529C142724271 @default.
• W3159808529 hasConceptScore W3159808529C197934379 @default.
• W3159808529 hasConceptScore W3159808529C204787440 @default.
• W3159808529 hasConceptScore W3159808529C22979827 @default.
• W3159808529 hasConceptScore W3159808529C27081682 @default.
• W3159808529 hasConceptScore W3159808529C2777488582 @default.
• W3159808529 hasConceptScore W3159808529C2778558090 @default.
• W3159808529 hasConceptScore W3159808529C2779134260 @default.
• W3159808529 hasConceptScore W3159808529C2779959927 @default.
• W3159808529 hasConceptScore W3159808529C42219234 @default.
• W3159808529 hasConceptScore W3159808529C71924100 @default.
• W3159808529 hasConceptScore W3159808529C90924648 @default.
• W3159808529 hasConceptScore W3159808529C98274493 @default.
• W3159808529 hasIssue "6" @default.

• next